Guided Therapeutics, Inc. (GTHP)

Market Cap	24.13M +14.3%
Revenue (ttm)	650.00K +450.8%
Net Income	-3.64M
EPS	-0.04
Shares Out	96.54M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	101
Open	0.1632
Previous Close	0.2700
Day's Range	0.1632 - 0.2500
52-Week Range	0.1500 - 0.5400
Beta	0.72
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2026

About Guided Therapeutics

Guided Therapeutics, Inc., a medical technology company, researches, develops, tests, manufactures, sells, and distributes medical devices in the United States and internationally. It offers LuViva, an advanced cervical scan non-invasive cervical cancer detection device that provides less invasive and painless alternative to conventional tests for identifying, screening, and detecting cervical cancers and precancers. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therap...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1992
• Employees: 3
• Stock Exchange: OTCMKTS
• Ticker Symbol: GTHP

Financial Performance

In 2025, Guided Therapeutics's revenue was $767,000, an increase of 10857.14% compared to the previous year's $7,000. Losses were -$3.35 million, 29.1% more than in 2024.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 25, 2026

Data Sources Report a data error